Editas Medicine, Inc. (EDIT)
2.17
+0.03
(+1.40%)
USD |
NASDAQ |
Nov 13, 16:00
2.165
0.00 (0.00%)
After-Hours: 19:59
Editas Medicine EPS Diluted (Quarterly) : -0.1523 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -0.1523 |
| June 30, 2026 | -0.1528 |
| March 31, 2026 | -0.2552 |
| December 31, 2025 | -0.0578 |
| September 30, 2025 | -0.2788 |
| June 30, 2025 | -0.6307 |
| March 31, 2025 | -0.9161 |
| December 31, 2024 | -0.5519 |
| September 30, 2024 | -0.7534 |
| June 30, 2024 | -0.8214 |
| March 31, 2024 | -0.756 |
| December 31, 2023 | -0.231 |
| September 30, 2023 | -0.5514 |
| June 30, 2023 | -0.5645 |
| March 31, 2023 | -0.7114 |
| December 31, 2022 | -0.8829 |
| September 30, 2022 | -0.8107 |
| June 30, 2022 | -0.7787 |
| March 31, 2022 | -0.7376 |
| December 31, 2021 | -0.6062 |
| September 30, 2021 | -0.5729 |
| June 30, 2021 | -0.8141 |
| March 31, 2021 | -0.8596 |
| December 31, 2020 | -1.004 |
| Date | Value |
|---|---|
| September 30, 2020 | 0.1247 |
| June 30, 2020 | -0.4259 |
| March 31, 2020 | -0.691 |
| December 31, 2019 | -0.7381 |
| September 30, 2019 | -0.6612 |
| June 30, 2019 | -0.6885 |
| March 31, 2019 | -0.5989 |
| December 31, 2018 | -0.5219 |
| September 30, 2018 | -0.3214 |
| June 30, 2018 | -0.82 |
| March 31, 2018 | -0.6727 |
| December 31, 2017 | -0.8496 |
| September 30, 2017 | -0.64 |
| June 30, 2017 | -0.65 |
| March 31, 2017 | -0.8523 |
| December 31, 2016 | -1.10 |
| September 30, 2016 | -0.59 |
| June 30, 2016 | -0.54 |
| March 31, 2016 | -0.80 |
| December 31, 2015 | -0.348 |
| September 30, 2015 | -2.566 |
| June 30, 2015 | -21.45 |
| March 31, 2015 | -2.752 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Vertex Pharmaceuticals, Inc. | 2.561 |
| Recursion Pharmaceuticals, Inc. | -0.2192 |
| Halozyme Therapeutics, Inc. | 2.015 |
| Novavax, Inc. | -0.1902 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -23.39M |
| Revenue (Quarterly) | 10.36M |
| Total Expenses (Quarterly) | 33.76M |
| Enterprise Value | 214.00M |
| Gross Profit Margin (Quarterly) | 96.29% |
| Profit Margin (Quarterly) | -225.7% |
| Earnings Yield | -28.48% |
| Normalized Earnings Yield | -30.92 |